News
NRSNW
0.0396
-1.00%
-0.0004
Weekly Report: what happened at NRSN last week (0928-1002)?
Weekly Report · 16h ago
SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Monday
Benzinga · 19h ago
NeuroSense Regains Nasdaq Bid Price Compliance, Appeals Market Value Delisting Notice
TipRanks · 3d ago
NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
Benzinga · 3d ago
NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71
NASDAQ · 3d ago
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
PR Newswire · 09/28 16:43
NeuroSense Therapeutics Price Target Raised to $52.00/Share From $8.00 by HC Wainwright & Co.
Dow Jones · 09/28 10:30
NeuroSense Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/28 10:30
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
Benzinga · 09/28 10:20
NeuroSense target adjusted to $52 from $8 at H.C. Wainwright
TipRanks · 09/28 10:20
Weekly Report: what happened at NRSN last week (0921-0925)?
Weekly Report · 09/28 09:48
NeuroSense H1 Net Loss Narrows; Targets December NDS Filing For PrimeC In ALS
NASDAQ · 09/28 07:40
NeuroSense Advances PrimeC ALS Program and Cuts Costs in H1 2026
TipRanks · 09/25 20:59
NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
Benzinga · 09/25 20:33
NeuroSense Therapeutics GAAP EPS of -$2.10 beats by $1.83
Seeking Alpha · 09/25 20:33
Weekly Report: what happened at NRSN last week (0914-0918)?
Weekly Report · 09/21 09:48
Weekly Report: what happened at NRSN last week (0907-0911)?
Weekly Report · 09/14 09:51
Neurosense Therapeutics Ltd trading halted, news pending
TipRanks · 09/11 23:50
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 09/09 21:06
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq
TipRanks · 09/09 20:58
More
Webull provides a variety of real-time NRSNW stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSNW
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease